Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study

American Journal of Medicine

Volumn 119, Issue 3, 2006, Pages 255-266

  Singh, Gurkirpal ^a   Fort, John G ^b   Goldstein, Jay L ^c   Levy, Roger A ^d   Hanrahan, Patrick S ^e   Bello, Alfonso E ^c   Andrade Ortega, Lilia ^f   Wallemark, Carl ^b   Agrawal, Naurang M ^g   Eisen, Glenn M ^h   Stenson, William F ⁱ   Triadafilopoulos, George ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f Hospital 20 de Noviembre   (Mexico)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular events; Celecoxib; Diclofenac; Gastrointestinal events; Naproxen; Nonsteroidal anti inflammatory agents; NSAID gastropathy; Osteoarthritis; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; CELECOXIB; DICLOFENAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGINA PECTORIS; ARTICLE; BRONCHITIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM PERFORATION; DYSPEPSIA; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOARTHRITIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH OBSTRUCTION; STOMACH PERFORATION; THROMBOEMBOLISM; ULCER; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS; PAIN; PYRAZOLES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 32844455611     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.09.054     Document Type: Article

References (40)

1. M.M. Wolfe, D.R. Lichtenstein, G. Singh Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1999 1888 1899
2. G. Singh, G. Triadafilopoulos Epidemiology of NSAID-induced GI complications J Rheumatol 26 suppl 1999 18 24
3. J.J. Deeks, L.A. Smith, M.D. Bradley Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis systematic review of randomised controlled trials BMJ 325 2002 619 626
4. E.F. Ekman, J.J. Fiechtner, S. Levy, J.G. Fort Efficacy of celecoxib versus ibuprofen in the treatment of acute pain a multicenter, double-blind, randomized controlled trial in acute ankle sprain Am J Orthop 31 2002 445 451
5. K. Saag, D. van der Heijde, C. Fisher Osteoarthritis Studies Group Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs a 6-week and a 1-year trial in patients with osteoarthritis Arch Fam Med 9 2000 1124 1134
6. P.P. Geusens, K. Truitt, P. Sfikakis A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis Scand J Rheumatol 31 2002 230 238
7. B.W. Morrison, S. Christensen, W. Yuan Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain a randomized, controlled trial Clin Ther 21 1999 943 953
8. J.L. Goldstein, F.E. Silverstein, N.M. Agrawal Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor Am J Gastroenterol 95 2000 1681 1690
9. M.J. Langman, D.M. Jensen, D.J. Watson Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1999 1929 1933
10. F.E. Silverstein, G. Faich, J.L. Goldstein Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 1247 1255
11. C. Bombardier, L. Laine, A. Reicin VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
12. T.J. Schnitzer, G.R. Burmester, E. Mysler Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications randomised controlled trial Lancet 364 2004 665 674
13. M.C. Hochberg, R.W. Chang, I. Dwosh, S. Lindsey, T. Pincus, F. Wolfe The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis Arthritis Rheum 35 1992 498 502
14. N. Bellamy Osteoarthritis clinical trials candidate variables and clinimetric properties J Rheumatol 24 1997 768 778
15. N. Bellamy, W.W. Buchanan, C.H. Goldsmith Validation study of WOMAC a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
16. Merck Research Laboratories. Vioxx Gastrointestinal Outcomes Research Study. Available at: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck. pdf. Accessed July 22, 2004.
17. A. Whitehead, J. Whitehead A general parametric approach to meta-analysis of randomized clinical trials Stat Med 10 1991 1665 1677
18. M. Mamdani, P.A. Rochon, D.N. Juurlink Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs BMJ 325 2002 624
19. J. Weil, D. Colin-Jones, M. Langman Prophylactic aspirin and risk of peptic ulcer bleeding BMJ 310 1995 827 830
20. B.F. McAdam, F. Catella-Lawson, I.A. Mardini Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2 the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci USA 96 1999 272 277 [published erratum appears in Proc Natl Acad Sci USA. 1999;96:5890]
21. G.A. FitzGerald, C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
22. R.S. Bresalier, R.S. Sandler, H. Quan Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
23. E. Ott, N.A. Nussmeier, P.C. Duke Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery J Thorac Cardiovasc Surg 125 2003 1481 1492
24. N.A. Nussmeier, A.A. Whelton, M.T. Brown Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 352 2005 1081 1091
25. Baraf HSB, Fuentealba C, Greenwald M, et al. Gastrointestinal tolerability and effectiveness of etoricoxib compared to diclofenac sodium in patients with osteoarthritis: a randomized, blinded clinical study (EDGE Trial). Poster presented at the American College of Rheumatology annual meeting, October 19, 2004.
26. W.B. White, G. Faich, A. Whelton Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac Am J Cardiol 89 2002 425 430
27. W.B. White, G. Faich, J.S. Borer, R.W. Makuch Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib Am J Cardiol 92 2003 411 418
28. M. Mamdani, P. Rochon, D.N. Juurlink Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly Arch Intern Med 163 2003 481 486
29. D.H. Campen, D. Graham, C. Cheetam Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective-nonsteroidal anti-inflammatory drugs [abstract 1756] Arthritis Rheum 50 suppl 9 2004 S657
30. S.E. Kimmel, J.A. Berlin, M. Reilly Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction Ann Intern Med 142 2005 157 164
31. W.A. Ray, C.M. Stein, J.R. Daugherty COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease Lancet 360 2002 1071 1073
32. D.H. Solomon, S. Schneeweiss, R.J. Glynn Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
33. S.D. Solomon, J.J. McMurray, M.A. Pfeffer Adenoma Prevention with Celecoxib (APC) Study Investigators Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
34. http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-hcp.pdf. Accessed January 12, 2005.
35. http://www.fda.gov/cder/drug/InfoSheets/HCP/Naproxen-hcp.pdf. Accessed January 12, 2005.
36. R. Chenevard, D. Hurlimann, M. Bechir Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 28 2003 107 405-409
37. M.F. Walter, R.F. Jacob, C.A. Day Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification comparison to sulfonamide COX-2 inhibitors and NSAIDs Atherosclerosis 177 2004 235 243
38. F.E. Silverstein, D.Y. Graham, J.R. Senior Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 241 249
39. T.M. MacDonald, S.V. Morant, G.C. Robinson Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure cohort study BMJ 315 1997 1333 1337
40. D. Schaffer, I. Marschner, C. Eagle The effect of exposure duration on NSAID-related serious gastrointestinal adverse event rates J Gastroentrol Hepatol 18 Suppl 2003 B15